Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target centered on LB-102, a Phase 3 oral schizophrenia asset built on a validated benzamide scaffold. In the firm’s view, this is a cleaner biotech setup where risk has shifted from biology to execution, with robust Phase 2 data already demonstrating a competitive efficacy and tolerability profile. Importantly, schizophrenia alone supports Craig-Hallum’s base case, while bipolar depression and major depressive disorder represent longer-term upside. The firm views LB Pharmaceuticals as an execution-driven story with favorable risk/reward into its next major catalyst.